Arbutus Biopharma Corporation
US ˙ NasdaqGS ˙ CA03879J1003

SecurityABUS / Arbutus Biopharma Corporation
InstitutionXTX Topco Ltd
Latest Disclosed Ownership40,021 shares
Latest Disclosed Value $ 180,095
XTX Topco Ltd ownership in ABUS / Arbutus Biopharma Corporation

On May 15, 2026 - XTX Topco Ltd filed a 13F-HR form disclosing ownership of 40,021 shares of Arbutus Biopharma Corporation (US:ABUS) valued at $180,094 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 0 shares of Arbutus Biopharma Corporation. The current value of the position is $174,091 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ARBUTUS BIOPHARMA COM 03879J100 40,021 40,021 180 0.0031
2026-02-17 2025-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 0 -11,364 -100.00 0 -100.00
2025-11-14 2025-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 11,364 -12,550 -52.48 52 -30.14 0.0027
2025-08-12 2025-06-30 13F ARBUTUS BIOPHARMA COM 03879J100 23,914 -48,498 -66.98 74 -71.03 0.0031
2025-05-08 2025-03-31 13F ARBUTUS BIOPHARMA COM 03879J100 72,412 19,831 37.72 253 47.37 0.0129
2025-02-13 2024-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 52,581 22,568 75.19 172 48.70 0.0141
2024-11-14 2024-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 30,013 12,975 76.15 116 121.15 0.0084
2024-08-12 2024-06-30 13F ARBUTUS BIOPHARMA COM 03879J100 17,038 17,038 53 0.0045
2023-02-14 2022-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 0 -39,755 -100.00 0 -100.00
2022-11-14 2022-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 39,755 -63,527 -61.51 76 -72.86 0.0188
2022-08-15 2022-06-30 13F ARBUTUS BIOPHARMA COM 03879J100 103,282 92,494 857.38 280 775.00 0.1144
2022-05-13 2022-03-31 13F ARBUTUS BIOPHARMA COM 03879J100 10,788 -18,238 -62.83 32 -71.68 0.0140
2022-02-11 2021-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 29,026 17,422 150.14 113 126.00 0.0639
2021-11-12 2021-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 11,604 11,604 50 0.0168
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.